NCT05564390 2026-03-18
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
17 trialsNCT03672539 2026-02-20
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03589729 2025-11-20
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04849910 2025-07-29
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Vor Biopharma
Phase 1/2 Terminated
NCT02117297 2023-10-26
SCT Plus Immune Therapy in Average Risk AML/MDS
New York Medical College
Phase 2 Completed
NCT02221310 2023-10-26
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
Phase 2 Completed
NCT01020539 2021-08-06
AML/MDS/JMML
Columbia University
Phase 1 Completed
NCT02272478 2020-01-23
AML18
Cardiff University
Phase 2/3 Unknown
NCT00038805 2018-10-31
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2/3 Terminated
NCT00669890 2015-04-22
High Risk
New York Medical College
Phase 1 Terminated
NCT00028899 2014-02-20
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Children's Oncology Group
Phase 1 Completed
NCT00882102 2013-09-13
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00454480 2013-08-26
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00195000 2013-06-19
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
Weill Medical College of Cornell University
Phase 2 Completed
NCT00968071 2013-03-08
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038831 2012-08-01
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00008151 2010-04-02
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed